IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDEAYA Biosciences Inc.

Ideaya Biosciences ($IDYA) announced an update on their ongoing clinical study. Ideaya Biosciences is running a new early-stage trial called “An Op...

Ideaya Advances IDE034 Into First-in-Human Trial for Advanced Solid Tumors

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA) and IDEAYA Bioscie...

Wall Street Analysts Are Bullish on Top Healthcare Picks

The latest update is out from IDEAYA Biosciences ( ($IDYA) ). On June 8, 2026, IDEAYA Biosciences entered into an underwriting agreement with a syn...

IDEAYA Biosciences Raises $324 Million in Equity Offering

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on IDEAYA Biosciences (IDYA) and Diaceutics (DIUXF). ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: IDEAYA Biosciences (IDYA) and Diaceutics (OtherDIUXF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biomea Fusion (BMEA) and IDEAYA Biosciences (IDYA) w...

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and IDEAYA Biosciences (IDYA)

IDEAYA Biosciences ( ($IDYA) ) has shared an announcement. On June 3, 2026, IDEAYA Biosciences announced a clinical collaboration with Roche to tes...

IDEAYA, Roche launch PRMT5 and pan-RAS collaboration

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Context Therapeutics (CNTX), IDEAYA Biosciences (IDY...

Analysts Offer Insights on Healthcare Companies: Context Therapeutics (CNTX), IDEAYA Biosciences (IDYA) and Edgewise Therapeutics (EWTX)

Guggenheim analyst Paul Jeng maintained a Buy rating on IDEAYA Biosciences today and set a price target of $54.00. Jeng covers the Healthcare secto...

IDEAYA Biosciences (IDYA) Receives a Buy from Guggenheim

The latest update is out from IDEAYA Biosciences ( ($IDYA) ). On June 1, 2026, IDEAYA Biosciences and Servier presented complete primary analysis d...

IDEAYA Highlights Positive Phase 2/3 Darovasertib Trial Results

Ideaya Biosciences ($IDYA) announced an update on their ongoing clinical study. Ideaya Biosciences is running a new study to test its drug IDE574 i...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IDYA	$31.23	-0.10%	2.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IDYA	$31.23	-0.1%	2.02M
3
4
5
6

IDYA

IDYA

No Data Available

Get IDEAYA Biosciences Inc. Data in Excel

Get IDEAYA Biosciences Inc. Data in Excel